+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Drug Addiction - Pipeline Review, H1 2019

  • ID: 4767142
  • Drug Pipelines
  • 181 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • BioCorRx Inc
  • Curemark LLC
  • F. Hoffmann-La Roche Ltd
  • Kyowa Hakko Kirin Co Ltd
  • Ovid Therapeutics Inc
  • MORE
Drug Addiction - Pipeline Review, H1 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Drug Addiction - Pipeline Review, H1 2019, provides an overview of the Drug Addiction (Central Nervous System) pipeline landscape.

Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. Drug addiction symptoms or behaviors include recurrent drug use that results in a lack of meeting important obligations at work, school, or home, inability to sleep, awake at unusual times, unusual laziness, loss of or increased in appetite, changes in eating habits, cold, sweaty palms; shaking hands., red, watery eyes; pupils larger or smaller than usual and unusual smells on breath, body or clothes.

Report Highlights

This latest pipeline guide Drug Addiction - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Drug Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Drug Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Drug Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 9, 30 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 13 and 3 molecules, respectively.

Drug Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Addiction (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Drug Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Drug Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Drug Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Drug Addiction (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Drug Addiction (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Drug Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • BioCorRx Inc
  • Curemark LLC
  • F. Hoffmann-La Roche Ltd
  • Kyowa Hakko Kirin Co Ltd
  • Ovid Therapeutics Inc
  • MORE
Introduction

Drug Addiction - Overview

Drug Addiction - Therapeutics Development

Drug Addiction - Therapeutics Assessment

Drug Addiction - Companies Involved in Therapeutics Development

Drug Addiction - Drug Profiles

Drug Addiction - Dormant Projects

Drug Addiction - Discontinued Products

Drug Addiction - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Drug Addiction, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Number of Products under Development by Companies, H1 2019 (Contd..2), H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Companies, H1 2019 (Contd..2), H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Target, H1 2019 (Contd..1), H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019 (Contd..1), H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Drug Addiction - Pipeline by Addex Therapeutics Ltd, H1 2019

Drug Addiction - Pipeline by Aelis Farma SAS, H1 2019

Drug Addiction - Pipeline by Aphios Corp, H1 2019

Drug Addiction - Pipeline by BioCorRx Inc, H1 2019

Drug Addiction - Pipeline by Charleston Laboratories Inc, H1 2019

Drug Addiction - Pipeline by Chiesi Farmaceutici SpA, H1 2019

Drug Addiction - Pipeline by Consegna Pharma Inc, H1 2019

Drug Addiction - Pipeline by Curemark LLC, H1 2019

Drug Addiction - Pipeline by Denovo Biopharma LLC, H1 2019

Drug Addiction - Pipeline by Egalet Corp, H1 2019

Drug Addiction - Pipeline by Embera NeuroTherapeutics Inc, H1 2019

Drug Addiction - Pipeline by F. Hoffmann-La Roche Ltd, H1 2019

Drug Addiction - Pipeline by Foresee Pharmaceuticals Co Ltd, H1 2019

Drug Addiction - Pipeline by IMV Inc, H1 2019

Drug Addiction - Pipeline by InterveXion Therapeutics LLC, H1 2019

Drug Addiction - Pipeline by Intra-Cellular Therapies Inc, H1 2019

Drug Addiction - Pipeline by KemPharm Inc, H1 2019

Drug Addiction - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2019

Drug Addiction - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2019

Drug Addiction - Pipeline by Novartis AG, H1 2019

Drug Addiction - Pipeline by Omeros Corp, H1 2019

Drug Addiction - Pipeline by Ovid Therapeutics Inc, H1 2019

Drug Addiction - Pipeline by P2D Inc, H1 2019

List of Figures

Number of Products under Development for Drug Addiction, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Top 10 Routes of Administration, H1 2019

Number of Products by Stage and Top 10 Routes of Administration, H1 2019

Number of Products by Top 10 Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Addex Therapeutics Ltd
  • Aelis Farma SAS
  • Aphios Corp
  • BioCorRx Inc
  • Charleston Laboratories Inc
  • Chiesi Farmaceutici SpA
  • Consegna Pharma Inc
  • Curemark LLC
  • Denovo Biopharma LLC
  • Egalet Corp
  • Embera NeuroTherapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Foresee Pharmaceuticals Co Ltd
  • IMV Inc
  • InterveXion Therapeutics LLC
  • Intra-Cellular Therapies Inc
  • KemPharm Inc
  • Kyorin Pharmaceutical Co Ltd
  • Kyowa Hakko Kirin Co Ltd
  • Novartis AG
  • Omeros Corp
  • Ovid Therapeutics Inc
  • P2D Inc
  • Protagenic Therapeutics Inc
  • Saniona AB
  • Sosei Heptares
  • SpringWorks Therapeutics LLC
  • Zynerba Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4767142
Adroll
adroll